Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in December

Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Approximately 16.3% of the company’s shares are short sold. Based on an average daily volume of 690,900 shares, the days-to-cover ratio is currently 15.9 days.

Organogenesis Trading Up 1.3 %

Shares of ORGO traded up $0.04 during trading hours on Tuesday, hitting $3.20. 522,404 shares of the stock were exchanged, compared to its average volume of 833,463. Organogenesis has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The business has a 50-day moving average of $3.46 and a 200-day moving average of $3.04. The firm has a market capitalization of $402.32 million, a P/E ratio of -53.33 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period last year, the business posted $0.02 EPS. On average, research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Buying and Selling

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the sale, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. This represents a 0.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 278,116 shares of company stock valued at $991,190 over the last 90 days. 36.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Organogenesis

A number of institutional investors and hedge funds have recently modified their holdings of the business. Verition Fund Management LLC boosted its stake in Organogenesis by 542.8% during the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after acquiring an additional 66,448 shares in the last quarter. FMR LLC grew its stake in shares of Organogenesis by 34.2% in the 3rd quarter. FMR LLC now owns 173,595 shares of the company’s stock valued at $496,000 after buying an additional 44,199 shares during the period. AQR Capital Management LLC increased its position in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after buying an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after acquiring an additional 333,123 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in shares of Organogenesis by 1,350.3% during the second quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after purchasing an additional 88,175 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.